Invictus MD Strategies's Enterprise Value for the quarter that ended in Oct. 2019 was $21.80 Mil.
Invictus MD Strategies's EBIT for the trailing twelve months (TTM) ended in Oct. 2019 was $-26.80 Mil. Invictus MD Strategies's Earnings Yield (Joel Greenblatt) for the quarter that ended in Oct. 2019 was -126.58%.
The historical rank and industry rank for Invictus MD Strategies's Earnings Yield (Joel Greenblatt) % or its related term are showing as below:
IVITF's Earnings Yield (Joel Greenblatt) % is not ranked *
in the Drug Manufacturers industry.
Industry Median: 2.53 * Ranked among companies with meaningful Earnings Yield (Joel Greenblatt) % only.
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. Invictus MD Strategies's Forward Rate of Return (Yacktman) % for the quarter that ended in Oct. 2019 was 0.00%. The Forward Rate of Return uses the normalized Free Cash Flow of the past seven years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.
Invictus MD Strategies Earnings Yield (Joel Greenblatt) % Historical Data
The historical data trend for Invictus MD Strategies's Earnings Yield (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Invictus MD Strategies Annual Data
Trend
Jan15
Jan16
Jan17
Jan18
Jan19
Earnings Yield (Joel Greenblatt) %
-6.68
2.81
-13.68
-13.85
-24.81
Invictus MD Strategies Quarterly Data
Jan15
Apr15
Jul15
Oct15
Jan16
Apr16
Jul16
Oct16
Jan17
Apr17
Jul17
Oct17
Jan18
Apr18
Jul18
Oct18
Jan19
Apr19
Jul19
Oct19
Earnings Yield (Joel Greenblatt) %
-24.10
-24.81
-37.04
-67.57
-126.58
Competitive Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Invictus MD Strategies's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Invictus MD Strategies Earnings Yield (Joel Greenblatt) % Distribution
For the Drug Manufacturers industry and Healthcare sector, Invictus MD Strategies's Earnings Yield (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Invictus MD Strategies's Earnings Yield (Joel Greenblatt) % falls into.
In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.
Invictus MD Strategiess Earnings Yield (Joel Greenblatt) for the fiscal year that ended in Jan. 2019 is calculated as
Invictus MD Strategies's EBIT for the trailing twelve months (TTM) ended in Oct. 2019 adds up the quarterly data reported by the company within the most recent 12 months, which was $-26.80 Mil.
Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.
Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.
Be Aware
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
Invictus MD Strategies Earnings Yield (Joel Greenblatt) % Related Terms
Thank you for viewing the detailed overview of Invictus MD Strategies's Earnings Yield (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.
Invictus MD Strategies (Invictus MD Strategies) Business Description
Invictus MD Strategies Corp is a cannabis company with a focus on the Canadian cannabis space, offering a selection of products under a wide range of cannabinoid profiles that fit the demand of the company's medical clients and retail customers. Its wholly-owned subsidiary's Phase I and Phase II facilities are in full production. The company's 50% owned subsidiary has completed its Phase II expansion and received its amended license from Health Canada. Another of its wholly owned subsidiary, connects medical clients to physicians for medical cannabis.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
IVITF has been successfully added to your 